Jorge Alejandro Torres-Ríos

Dr. Jorge Alejandro Torres-Ríos

Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ARAlejandro Rodríguez-Camacho
Alejandro Rodríguez-Camacho
JVJosé Guillermo Flores Vázquez
José Guillermo Flores Vázquez
JMJúlia Moscardini-Martelli
Júlia Moscardini-Martelli
JTJorge Alejandro Torres-Ríos
Jorge Alejandro Torres-Ríos
AOAlejandro Olmos-Guzmán
Alejandro Olmos-Guzmán
SMSergio Moreno-Jiménez
Sergio Moreno-Jiménez
(1) Background: Glioblastoma is the most frequent and lethal primary tumor of the central nervous system. Through many years, research has brought various advances in glioblastoma treatment. At this time, glioblastoma management is based on maximal safe surgical resection, radiotherapy, and chemotherapy with temozolomide. Recently, bevacizumab has been added to the treatment arsenal for the recurrent scenario. Nevertheless, patients with glioblastoma still have a poor prognosis. Therefore, many efforts are being made in different clinical research areas to find a new alternative to improve overall survival, free-progression survival, and life quality in glioblastoma patients. (2) Methods: Our objective is to recap the actual state-of-the-art in glioblastoma treatment, resume the actual research and future perspectives on immunotherapy, as well as the new synthetic molecules and natural compounds that represent potential future therapies at preclinical stages. (3) Conclusions: Despite the great efforts in therapeutic research, glioblastoma management has suffered minimal changes, and the prognosis remains poor. Combined therapeutic strategies and delivery methods, including immunotherapy, synthetic molecules, natural compounds, and glioblastoma stem cell inhibition, may potentiate the standard of care therapy and represent the next step in glioblastoma management research.

Verified
Journal Article
Open access
PDF file
MAMauricio Muleiro Alvarez
Mauricio Muleiro Alvarez
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
MMMaria Fernanda Osorio Martinez
Maria Fernanda Osorio Martinez
JGJoaquin Vega Gonzales-Portillo
Joaquin Vega Gonzales-Portillo
GMGerman Rivera Monroy
German Rivera Monroy
Antonio IbarraAntonio Ibarra
Antonio Ibarra
Parkinson’s disease (PD) is a gradually worsening neurodegenerative disorder affecting the nervous system, marked by a slow progression and varied symptoms. It is the second most common neurodegenerative disease, affecting over six million people in the world. Its multifactorial etiology includes environmental, genomic, and epigenetic factors. Clinical symptoms consist of non-motor and motor symptoms, with motor symptoms being the classic presentation. Therapeutic approaches encompass pharmacological, non-pharmacological, and surgical interventions. Traditional pharmacological treatment consists of administering drugs (MAOIs, DA, and levodopa), while emerging evidence explores the potential of antidiabetic agents for neuroprotection and gene therapy for attenuating parkinsonian symptoms. Non-pharmacological treatments, such as exercise, a calcium-rich diet, and adequate vitamin D supplementation, aim to slow disease progression and prevent complications. For those patients who have medically induced side effects and/or refractory symptoms, surgery is a therapeutic option. Deep brain stimulation is the primary surgical option, associated with motor symptom improvement. Levodopa/carbidopa intestinal gel infusion through percutaneous endoscopic gastrojejunostomy and a portable infusion pump succeeded in reducing “off” time, where non-motor and motor symptoms occur, and increasing “on” time. This article aims to address the general aspects of PD and to provide a comparative comprehensive review of the conventional and the latest therapeutic advancements and emerging treatments for PD. Nevertheless, further studies are required to optimize treatment and provide suitable alternatives.

Verified
Journal Article
Open access
PDF file
JMJúlia Moscardini-Martelli
Júlia Moscardini-Martelli
ARAlejandro Rodríguez-Camacho
Alejandro Rodríguez-Camacho
JTJorge Alejandro Torres-Ríos
Jorge Alejandro Torres-Ríos
JSJuan Marcos Meraz Soto
Juan Marcos Meraz Soto
JVJosé Guillermo Flores Vázquez
José Guillermo Flores Vázquez
SMSergio Moreno-Jiménez
Sergio Moreno-Jiménez
Seventy years ago, Robin Mole introduced the concept of the abscopal effect to describe a rare phenomenon. This occurs when local radiation triggers an immune-mediated reduction in tumors outside the treated area but within the same organism. Observing this effect has been linked to improved overall and progression-free survival in patients who experience it. While the abscopal effect was once considered rare, it is now being observed more frequently due to the combination of radiation with immunotherapy. As a result, more researchers are exploring this study area, which shows promise for excellent results. This review focuses explicitly on the immunological implications of activating the abscopal effect through ionizing radiation in the central nervous system and explores the potentially involved immunological pathways.

9 March 2024 in World Neurosurgery: X
Verified
Journal Article
Open access
JTJorge Alejandro Torres-Ríos
Jorge Alejandro Torres-Ríos
ARAlejandro Rodríguez-Camacho
Alejandro Rodríguez-Camacho
EBEstefania Basilio-Tomé
Estefania Basilio-Tomé
JMJuan Marcos Meraz-Soto
Juan Marcos Meraz-Soto
ACAzyadeh Camacho-Ordonez
Azyadeh Camacho-Ordonez
SMSergio Moreno-Jiménez
Sergio Moreno-Jiménez
Our primary objective is to evaluate the local control of optic nerve sheath meningiomas (ONSMs) treated with ionizing radiation and related visual changes after treatment. Our secondary objective is to describe the clinical characteristics and perform an analysis of the treatment impact on the functional status of this group of patients. We present our series of 19 patients treated with ionizing radiation therapy at our radio-neurosurgery unit between 2016 and 2022. The setting, ophthalmological follow-up, morbidity, and survival are analyzed and discussed. Patients were followed up, and the impact of treatment on local disease control, visual alterations of the affected eye, and functional status of the patient were analyzed. The progression-free survival (PFS) median was 60 months (95% CI 50.3–69.6 months). The estimated PFS rates at 48 and 66 months were 100% and 66%, respectively. At diagnosis, nine (47.3%) eyes were in amaurosis and ten (52.6%) with vision. Of the ten patients without amaurosis at the time of diagnosis, three (30%) maintained unchanged visual acuity, and seven (70%) had decreased visual acuity; three of them developed amaurosis during the first year after treatment (p = 0.018). Using ionizing radiation therapy is a successful treatment for the local control of ONSMs. This therapeutic modality can compromise the visual acuity of the affected eye and improve dyschromatopsia and campimetry defects. The life prognosis is good for these patients, with a zero mortality rate, but their vision prognosis is poor.

10 November 2022 in Cureus
Verified
Journal Article
Open access
KAKeren Magaly Aguilar-Hidalgo
Keren Magaly Aguilar-Hidalgo
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
JSJosé Omar Santellán-Hernández
José Omar Santellán-Hernández
ACAna Laura Calderón-Garcidueñas
Ana Laura Calderón-Garcidueñas
GRGerardo Romero-Luna
Gerardo Romero-Luna
SPSonia iliana Mejia Perez
Sonia iliana Mejia Perez
Gangliogliomas are central nervous system (CNS) tumors with a neuronal and glial component considered grade 1 according to the World Health Organization (WHO) classification. On the other hand, oligodendrogliomas are diffuse infiltrating gliomas (CNS WHO grade 2 or 3) characterized by both an isocitrate dehydrogenase mutation and 1p/19q co-deletion. There have been some cases with the coexistence of these two tumors. Here, we present the case of a low-growing left frontoparietal brain tumor with a definite diagnosis of ganglioglioma (CNS WHO grade 1) and oligodendroglioma (CNS WHO grade 2) with areas of anaplastic oligodendroglioma (CNS WHO grade 3) in a patient with long-standing epilepsy.

2 November 2022
Verified
Book Chapter
Open access
PDF file
DMDaniel Arturo Martínez-Piña
Daniel Arturo Martínez-Piña
GAGustavo Alexis Alvarado-Fernández
Gustavo Alexis Alvarado-Fernández
EGEdith González-Guevara
Edith González-Guevara
CCCarlos Castillo-Pérez
Carlos Castillo-Pérez
GRGerardo Romero-Luna
Gerardo Romero-Luna
JTJorge Alejandro Torres-Ríos
Jorge Alejandro Torres-Ríos
Glucose provides the necessary fuel to cover the physiological functions of the organism. In the brain, glucose represents the main energy supply through the generation of adenosine triphosphate, with oxygen and glucose being the main components involved. The imbalance in glucose levels in the central nervous system produces substantial changes in metabolism. Hypoglycemia, or decreased blood glucose levels below 50 mg/dl, is accompanied by symptoms such as decreased performance of cognitive tasks such as verbal fluency, reaction time, arithmetic ability, verbal memory and visual, in addition to excitotoxicity, oxidative stress, neuroinflammation and apoptosis. Hyperglycemia participates in some cardiovascular diseases, neuropathy, nephropathy, retinopathy. Changes in glucose metabolism must be regulated and considered in order to obtain the best treatment for different pathologies, such as infections, non-infections, traumatic, primary or acquired.